Identifying Subphenotypes of Antibody-Mediated Rejection in Kidney Transplants

American Journal of Transplantation

Volumn 16, Issue 3, 2016, Pages 908-920

  Halloran, P F ^a,b   Merino Lopez, M ^a   Barreto Pereira, A ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Santa Julia Hospital   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C4D; CYCLOSPORIN; HLA ANTIBODY; MYCOPHENOLATE MOFETIL; STEROID; TACROLIMUS; AUTOANTIBODY; HLA ANTIGEN;

ADULT; AGED; ANTIBODY MEDIATED KIDNEY TRANSPLANT REJECTION; ANTIBODY MEDIATED REJECTION; ARTICLE; BIOPSY; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DETERIORATION; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HEALTH CARE QUALITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MEDICATION COMPLIANCE; MICROCIRCULATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHENOTYPE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; SURVIVAL; T LYMPHOCYTE MEDIATED REJECTION; TRANSPLANT GLOMERULOPATHY; ADOLESCENT; ADVERSE EFFECTS; BLOOD; CLASSIFICATION; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; T LYMPHOCYTE; TRANSPLANTATION TOLERANCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; T-LYMPHOCYTES; TRANSPLANT RECIPIENTS; TRANSPLANTATION TOLERANCE; YOUNG ADULT;

EID: 84959543767     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13551     Document Type: Article

References (43)

1. Lamb KE, Lodhi S, Meier-Kriesche HU., Long-term renal allograft survival in the United States: A critical reappraisal. Am J Transplant 2011; 11: 450-462.
2. Gaston RS, Cecka JM, Kasiske BL, et al., Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplant 2010; 90: 68-74.
3. Loupy A, Suberbielle-Boissel C, Hill GS, et al., Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
4. Halloran PF, Chang J, Famulski K, et al., Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients. JASN 2015; 26: 1711-1720.
5. Einecke G, Sis B, Reeve J, et al., Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
6. Hidalgo LG, Campbell PM, Sis B, et al., De novo donor specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9: 2532-2541.
7. Haas M, Sis B, Racusen LC, et al., Banff 2013 Meeting Report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272-283.
8. Halloran PF, Merino Lopez M, Salazar IDR, Chang J,. Clinical Subclassifiation of ABMR phenotypes: Recognizing variation in presentation. Am J Transpl 2015; 15: 1.
9. Reeve J, Sellares J, Mengel M, et al., Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies. Am J Transplant 2013; 13: 645-655.
10. Sellares J, Reeve J, Loupy A, et al., Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 2013; 13: 971-983.
11. Halloran PF, Pereira AB, Chang J, et al., Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: The INTERCOM study. Am J Transplant 2013; 13: 2352-2363.
12. Halloran PF, Pereira AB, Chang J, et al., Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: An international prospective study (INTERCOM). Am J Transplant 2013; 13: 2865-2874.
13. Sellares J, De Freitas D, Mengel M, et al., Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and non-adherence. Am J Transplant 2012; 12: 388-399.
14. Solez K, Colvin RB, Racusen LC, et al., Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753-760.
15. Salazar IDR, Lopez MM, Chang J, Halloran PF., Reassessing the significance of v lesions in kidney transplant biopsies. J Am Soc Nephrol 2015; 26: 3190-3198.
16. Reeve J, Einecke G, Mengel M, et al., Diagnosing rejection in renal transplants: A comparison of molecular- and histopathology-based approaches. Am J Transplant 2009; 9: 1802-1810.
17. Sis B, Jhangri GS, Riopel J, et al., A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168-1179.
18. Reeve J, Famulski K, Halloran PF, and the INTERCOM group. Microarray gene expression for predicting histo-clinical variables in kidney transplant biopsies (abstract). Am J Transpl 2014; 14: 890.
19. Sis B, Einecke G, Chang J, et al., Cluster analysis of lesions in kidney transplant biopsies: Microcirculation changes, tubulointerstitial inflammation, and scarring. Am J Transplant 2010; 10: 421-430.
20. Porter KA, Dossetor JB, Marchioro TL, et al., Human renal transplants: I. Glomerular changes. Lab Invest 1967; 16: 153-181.
21. Maryniak RK, First MR, Weiss MA., Transplant glomerulopathy: Evolution of morphologically distinct changes. Kidney Int 1985; 27: 799-806.
22. Regele H, Bohmig GA, Habicht A, et al., Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371-2380.
23. Gloor JM, Sethi S, Stegall MD, et al., Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 2007; 7: 2124-2132.
24. Baid-Agrawal S, Farris AB III, Pascual M, et al., Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 2011; 80: 879-885.
25. Feucht HE, Schneeberger H, Hillebrand G, et al., Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333-1338.
26. Feucht HE., Complement C4d in graft capillaries: The missing link in the recognition of humoral alloreactivity. Am J Transplant 2003; 3: 646-652.
27. Mauiyyedi S, Pelle PD, Saidman S, et al., Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574-582.
28. Middleton D, Jones J, Lowe D., Nothing's perfect: The art of defining HLA-specific antibodies. Transplant Immunol 2014; 30: 115-121.
29. Visentin J, Guidicelli G, Bachelet T, et al., Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: Prevalence, relevance, and impact on organ allocation. Clin Translat Res 2014; 98: 738-744.
30. Gombos P, Opelz G, Scherer S, et al., Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Am J Transplant 2013; 13: 2075-2082.
31. Gebel HM, Bray RA., In search of perfection. Am J Transplant 2013; 13: 1951-1952.
32. Lachmann N, Terasaki PI, Budde K, et al., Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplant 2009; 87: 1505-1513.
33. Zou Y, Stastny P, Susal C, Dohler B, Opelz G., Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357: 1293-1300.
34. Halloran PF,. Transplantation: Autoantibodies: Epiphenomena or biological clues. Nat Rev Nephrol 2013; 9: 705-706.
35. Lefaucheur C, Loupy A, Vernerey D, et al., Antibody-mediated vascular rejection of kidney allografts: A population-based study. Lancet 2013; 381: 313-319.
36. Cosio FG, Gloor JM, Sethi S, Stegall MD., Transplant glomerulopathy. Am J Transplant 2008; 8: 492-496.
37. Loupy A, Lefaucheur C, Vernerey D, et al., Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. JASN 2014; 52: 2267-2277.
38. Loupy A, Suberbielle-Boissel C, Zuber J, et al., Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: A pilot study. Transplant 2010; 89: 1403-1410.
39. Nabokow A, Dobronravov VA, Khrabrova M, et al., Long-term kidney allograft survival in patients with transplant glomerulitis. Transplant 2015; 99: 331-339.
40. Lesage J, Noel R, Lapointe I, et al., Donor-specific antibodies, C4d and their relationship with the prognosis of transplant glomerulopathy. Transplant 2015; 99: 69-76.
41. Einecke G, Reeve J, Sis B, et al., A molecular classifier for predicting future graft loss in late kidney transplant biopsies. J Clin Invest 2010; 120: 1862-1872.
42. Famulski KS, Reeve J, de Freitas DG, et al., Kidney transplants with progressing chronic kidney diseases express high levels of acute kidney injury transcripts. Am J Transplant 2013; 13: 634-644.
43. Jameson JL, Longo DL,. Precision medicine: Personalized, problematic, and promising. N Engl J Med 2015; 372: 2229-2234.